

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 58796

**Title:** The pathological significance of abnormal RON and PD- Y expression in colorectal cancer

**Reviewer's code:** 05128663

**Position:** Peer Reviewer

**Academic degree:** BSc, MD, MSc, PhD

**Professional title:** Academic Research, Attending Doctor, Postdoc, Research Associate, Research Fellow

**Reviewer's Country/Territory:** Greece

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-08-09

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-08-09 16:41

**Reviewer performed review:** 2020-08-15 16:59

**Review time:** 6 Days

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

The article with the title “The pathological significance of abnormal RON and PD-L1 expression in colorectal cancer” is in generally well done, but I would offer these comments to the investigators: 1) Figure 6. I highly recommend to check also downstream agents of AKT such as mTOR, ps6r etc. 2) i) Figure 6 A. The authors identified the activation of the signaling pathways MEK/ERK and AKT/mTOR. Both pathways are regulators of autophagy, a significant mechanism for several cellular processes including the emerging role of autophagy in shaping the crosstalk between the cancer cells and the tumor microenvironment and PD-L1 expression in cancer cells. I recommend the authors to perform an experiment in order to identify the levels of autophagy markers such as LC3II, p62, Beclin-1. You can discuss the possible correlation between autophagy activation and PD-L1 expression. Koustas E, et al. PLoS One. 2018;13(11):e0207227. doi: 10.1371/journal.pone.0207227. Koustas E, et al. Cancers (Basel). 2019;11(4):533 doi: 10.3390/cancers11040533. ii) If autophagy is activated, an autophagy inhibitor such as Hydroxychloroquine will reveal a possible mechanism of action for your model. 3) It is properly to mention that the antibody against p-AKT detects the endogenous levels of Akt only when phosphorylated at Ser473. Because the complicate mechanisms of PI3K/AKT/mTOR axis activation with the positive feedback loop (AKTthr308, ser473, mTOR1 and mTOR2) on autophagy, I believe that it will be useful to discuss it. 4) All sections need to be revised to take into account all revisions made.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 58796

**Title:** The pathological significance of abnormal RON and PD- Y expression in colorectal cancer

**Reviewer's code:** 05275248

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Associate Researcher

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-08-09

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-08-10 01:29

**Reviewer performed review:** 2020-08-16 08:45

**Review time:** 6 Days and 7 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

1. The section of patient demographics in Results should be shown in M&M, and “Expression patterns of RON and PD-L1 in the GEO cohort” should be described in detail. 2. In general, authors should use more than 2 cell lines to validated their findings in in vitro experiments. I am puzzled why LoVo cells with lower toxicity was not used, which appeared in Supplemental. 3. It is unreasonable for authors to assess the relationship between RON and PD-L1 by a multiplex immunofluorescence staining. They should use quantitative assays such as RT-PCR and ELISA, etc. 4. Fig 3c which should be replaced by new one is too difficult to distinguish; 5. The number of cells is too few in Fig 5a; Phosphorylated RON should also detected in Fig 5b. The picture quality of PD-L1 in Fig 5b should be improved. 6. Authors should supply with some information and intention in this study of inhibitor MSP.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 58796

**Title:** The pathological significance of abnormal RON and PD- expression in colorectal cancer

**Reviewer's code:** 05275248

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Associate Researcher

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-08-09

**Reviewer chosen by:** Ze-Mao Gong

**Reviewer accepted review:** 2020-09-08 03:32

**Reviewer performed review:** 2020-09-08 03:38

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

The authors have revised the manuscript in accordance with comments.